Browsing by Subject "JAK1 inhibitor"
Now showing items 1-1 of 1
-
(Elsevier, 2022)Background: The heterogeneous course of moderate-to-severe atopic dermatitis necessitates treatment flexibility. Objective: We evaluated the maintenance of abrocitinib-induced response with continuous abrocitinib ...